Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Opus Genetics, Inc.IRD · Entity 5892 | Director | April 20, 2026 | April 22, 2026 |
| REGENXBIO Inc.RGNX · Entity 2211 | Director | May 29, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Opus Genetics, Inc.
Report date April 20, 2026 · Filed April 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 259,019 |
Reported balance
After 2026-04-20 transaction · row 1
1 source rowRow 1 · 2026-04-20 · Grant · Acquired 24,367 · Balance 259,019 F1: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date.
REGENXBIO Inc.
Report date May 29, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,861 |
Reported balance
After 2026-05-29 transaction · row 1
1 source rowRow 1 · 2026-05-29 · Grant · Acquired 9,807 · Balance 28,861 F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2036-05-29 | Direct | 46,600 |
Reported balance
After 2026-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-29 · Grant · Acquired 46,600 · Balance 46,600 F2: The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer.
F2: The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2026 Filed Jun 2, 2026 21:15 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to Buy) · Derivative | 46,600 | $0.00 Strike: $7.01 | $0.00 |
DisclosureSEC source: 0001872219-26-000001 · primarydocument.xml · derivative · entry 2 Bennett Jean · CIK 0001872219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,600 Underlying: Common Stock · 46,600 shares Expires 2036-05-29 F2 · derivative.exercise_date: The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 21:15 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 9,807 | $0.00 | $0.00 |
DisclosureSEC source: 0001872219-26-000001 · primarydocument.xml · nonDerivative · entry 1 Bennett Jean · CIK 0001872219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,861 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:28 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 24,367 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-001782 · form4.xml · nonDerivative · entry 1 Bennett Jean · CIK 0001872219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 259,019 F1 · shares: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 21:21 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 21,127 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-26-000028 · form4.xml · nonDerivative · entry 1 Bennett Jean · CIK 0001872219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,652 F1 · price: The Reporting Person was granted shares of common stock in lieu of cash for board services for 2026. The number of shares was determined by dividing (A) the aggregate amount of the retainer to be earned for board services for such period, by (B) the average fair market value of a share of common stock the day prior to the grant date (rounded down to the nearest whole share). The average fair market value was $1.99 per share, the average of the high and low price of the common stock, the day prior to the grant date. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:31 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to Buy) · Derivative | 39,815 | $0.00 Strike: $8.85 | $0.00 |
DisclosureSEC source: 0001562180-25-004347 · primarydocument.xml · derivative · entry 2 Bennett Jean · CIK 0001872219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,815 Underlying: Common Stock · 39,815 shares Expires 2035-05-30 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 30, 2025 subject to the continuous service of the optionee to the Issuer. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:31 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 7,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-004347 · primarydocument.xml · nonDerivative · entry 1 Bennett Jean · CIK 0001872219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,054 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 1, 2026 subject to the continuous service of the recipient to the Issuer. Read SEC document |
| April 30, 2025 Filed May 2, 2025 21:03 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantStock Option (Right to Buy) · Derivative | 79,592 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0000905148-25-001425 · form4.xml · derivative · entry 2 Bennett Jean · CIK 0001872219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,592 Underlying: Common Stock · 79,592 shares Expires 2035-04-29 F2 · derivative.exercise_date: The option will vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| April 30, 2025 Filed May 2, 2025 21:03 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 79,504 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-001425 · form4.xml · nonDerivative · entry 1 Bennett Jean · CIK 0001872219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,525 F1 · shares: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:42 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 34,021 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-25-000038 · form4.xml · nonDerivative · entry 1 Bennett Jean · CIK 0001872219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,021 F1 · price: The Reporting Person was granted shares of common stock in lieu of cash for board services for 2025. The number of shares was determined by dividing (A) the aggregate amount of the retainer to be earned for board services for such period, by (B) the average fair market value of a share of common stock on the grant date (rounded down to the nearest whole share). The average fair market value was $1.23 per share, the average of the high and low price of the common stock on the date of grant. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 21:56 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantStock Option (right to buy) · Derivative | 172,874 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0000905148-24-002827 · form4.xml · derivative · entry 2 Bennett Jean · CIK 0001872219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,874 Underlying: Common Stock · 172,874 shares Expires 2034-10-21 F2 · derivative.exercise_date: The option will vest in a series of three equal annual installments over the three-year period measured from the grant date of October 22, 2024, subject to the Reporting Person's continuing service. Read SEC document |
| October 22, 2024 Filed Oct 24, 2024 21:56 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-002827 · form4.xml · nonDerivative · entry 1 Bennett Jean · CIK 0001872219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 F1 · shares: Represents a grant of restricted stock units which vest on the one-year anniversary of the grant date of October 22, 2024, subject to the Reporting Person's continuing service. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:41 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to Buy) · Derivative | 24,454 | $0.00 Strike: $14.35 | $0.00 |
DisclosureSEC source: 0001562180-24-004652 · primarydocument.xml · derivative · entry 2 Bennett Jean · CIK 0001872219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,454 Underlying: Common Stock · 24,454 shares Expires 2034-05-31 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 31, 2024 subject to the continuous service of the optionee to the Issuer. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:41 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 4,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-004652 · primarydocument.xml · nonDerivative · entry 1 Bennett Jean · CIK 0001872219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,286 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 1, 2025 subject to the continuous service of the recipient to the Issuer. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 21:11 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to Buy) · Derivative | 17,892 | $0.00 Strike: $19.72 | $0.00 |
DisclosureSEC source: 0001562180-23-004889 · primarydocument.xml · derivative · entry 2 Bennett Jean · CIK 0001872219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,892 Underlying: Common Stock · 17,892 shares Expires 2033-06-02 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following June 2, 2023 subject to the continuous service of the optionee to the Issuer. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 21:11 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 3,486 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-004889 · primarydocument.xml · nonDerivative · entry 1 Bennett Jean · CIK 0001872219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,496 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 1, 2024 subject to the continuous service of the recipient to the Issuer. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 20:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 15,324 | $0.00 Strike: $22.84 | $0.00 |
DisclosureSEC source: 0001562180-22-004873 · primarydocument.xml · derivative · entry 2 Bennett Jean · CIK 0001872219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,324 Underlying: Common Stock · 15,324 shares Expires 2032-06-03 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following June 3, 2022 while the optionee provides continuous service to the Issuer. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 20:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 3,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-004873 · primarydocument.xml · nonDerivative · entry 1 Bennett Jean · CIK 0001872219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,010 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 1, 2023 while the recipient provides continuous service to the Issuer. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 20:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $34.98 | $0.00 |
DisclosureSEC source: 0001562180-21-005878 · primarydocument.xml · derivative · entry 1 Bennett Jean · CIK 0001872219 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-09-03 F1 · derivative.exercise_date: The option will vest in equal monthly installments over the 36 months following September 3, 2021, with immediate full vesting in the event of a change in control. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.